Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer : 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

DSpace/Manakin Repository

 
 
See more statistics about this item